4:08 PM
 | 
Aug 20, 2012
 |  BC Extra  |  Company News

Pharmacyclics earns $50M milestone on ibrutinib trial start

Pharmacyclics Inc. (NASDAQ:PCYC) will receive a $50 million payment from partner Janssen Biotech Inc. after the Johnson & Johnson (NYSE:JNJ) unit enrolled the fifth patient in...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >